Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 4/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30895351 | 0.80 | GPR119 (0.39) | PDE4BHSD11B1GRM2ARPARP1 | |
| SCHEMBL19959353 | 0.80 | GPR119 (0.39) | PDE4BHSD11B1GRM2ARPARP1 | |
| SCHEMBL14117916 | 0.72 | ATM (0.45) | ATMALDH1A1KMT2A | |
| SCHEMBL780002 | 0.70 | USP30 (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2954128 | 0.70 | USP30 (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2943987 | 0.70 | USP30 (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL15304847 | 0.70 | MEN1 (0.41) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL15344697 | 0.70 | MEN1 (0.41) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL9965481 | 0.69 | ATM (0.45) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL642245 | 0.69 | ATM (0.45) | ATMALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885ALDH1A1 3370/4885MEN1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.